Bristol Myers’ $4.1B Turning Point buy yields FDA approval for lung cancer drug Augtyro

Fierce Pharma November 16, 2023
Angus Liu

Watch out, Pfizer and Roche. Thanks to an acquisition and now an FDA approval, Bristol Myers Squibb is entering a niche lung cancer market.

The FDA has cleared Bristol Myers’ repotrectinib, to be branded as Augtyro, to treat non-small cell lung cancer (NSCLC) patients whose tumors have ROS1 oncogenic fusions. The New Jersey pharma company said it plans to make the drug available starting in mid-December.

BMS got Augtyro through its $4.1 billion acquisition of Turning Point Therapeutics last year. And Wednesday’s approval gives BMS an opportunity to challenge Pfizer’s Xalkori and Roche’s Rozlytrek in ROS1-positive NSCLC, which accounts for about 1% to 2% of all NSCLC cases.

Augtyro could reach $1.4 billion sales at peak in the first-line...

Today's Sponsors

Today's Sponsor